原著・論文（審査を経た論文）

2024年

• An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study)

  Abe Y, Kubonishi S , Ri M, Iino M, Sunami K, Ito T, Fukaya M, Kitano T, Ikeda S, Ota S, Kuroi T, Iriyama N, Jo T, Adachi M, Akahane D, Kai T, Kohara Y, Kadowaki N, Katayama T. Future Oncol. 2024 Feb 29. doi: 10.2217/fon-2023-0834. Online ahead of print.

• Development and evaluation of a rapid one-step high sensitivity real-time quantitative PCR system for minor BCR-ABL (e1a2) test in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

  Hidaka M, Inokuchi K, Uoshima N, Takahashi N, Yoshida N, Ota S, Nakamae H, Iwasaki H, Watanabe K, Kosaka Y, Komatsu N, Meguro K, Najima Y, Eto T, Kondo T, Kimura S, Yoshida C, Ishikawa Y, Sawa M, Hata T, Horibe K, Iida H, Shimomura T, Dobashi N, Sugiura I, Makiyama J, Miyagawa N, Sato A, Ito R, Matsumura I, Kanakura Y, Naoe T. Jpn J Clin Oncol. 2024 Feb 7;54(2):153-159.

• Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy

  Sato H, Kobayashi T, Kameoka Y, Teshima K, Watanabe A, Yamada M, Yamashita T, Noguchi S, Michisita Y, Fujishima N, Kuroki J, Takahashi N. Int J Clin Oncol. 2024 Apr;29(4):481-492.

• A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan

  Horigome Y, Iino M, Harazaki Y, Kobayashi T, Handa H, Hiramatsu Y, Kuroi T, Tanimoto K, Matsue K, Abe M, Ishida T, Ito S, Iwasaki H, Kuroda J, Shibayama H, Sunami K, Takamatsu H, Tamura H, Hayashi T, Akagi K, TMaeda T, Yoshida T, Mori I, Shinozaki T & Iida S. Ann Hematol. 2024 Feb;103(2):475-488.

2023年

• [Sustaining molecular response with very low dose ponatinib and further response after hemodialysis initiation in a patient with chronic myeloid leukemia]

  Sato K, Sumi M, Kobayashi M, Kataoka K, Takahashi N, Kobayashi H. Rinsho Ketsueki. 2023;64(10):1266-1269.

• [Next treatment for TKI-resistant CML]

  Takahashi N. Rinsho Ketsueki. 2023;64(9):981-987.

• [Refractory esophageal stricture of esophageal mucous membrane pemphigoid after allogeneic hematopoietic stem cell transplantation]

  Fujita N, Yamashita T, Abe F, Nara M, Yoshioka T, Koga H, Ishii N, Takahashi N. Rinsho Ketsueki. 2023;64(2):107-112.

• Ponatinib Improved the Prognosis of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Japanese Single- Center Cohort Study

  Tozawa N, Yamashita T, Nara M, Fujioka Y, Ikeda S , Kobayashi T, Kobayashi I, Kitadate A, Kameoka K, Takahashi N. Cureus. 2023 Dec 12;15(12):e50416.

• Quantitation of Venetoclax in Human Plasma by High-Performance Liquid Chromatography with Ultraviolet Detection

  Fukuda N, Kobayashi T, Sato H, Akamine Y, Takahashi N, Miura M. J Chromatogr Sci. 2023 Dec 30;62(1):58-64.

• Nation-wide Cohort Study of Remission Induction Therapy using Rituximab in Japanese patients with ANCA-Associated Vasculitis: effectiveness and safety in the first six months

  Nagasaka K, Amano K, Dobashi H, Nagafuchi H,Sada K, Komagata Y, Yamamura M, Kato M, Endo T, Nakaya I, Takeuchi T, Murakawa Y, Sugihara T, Saito M, Hayashi T, Furuta S, Tamura N, Karasawa K,  Banno S, Endo S, Majima M, Kaname S, Arimura Y, Harigai M. Mod Rheumatol .2023 Nov 1;33(6):1117-1124.

• c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma

  Osada N, Kikuchi J, Iha H, Yasui H, Ikeda S, Takahashi N, Furukawa Y. Clin Transl Med. 2023 Aug;13(8):e1364.

• Clinical Course of a Rare Epstein-Barr Virus-Associated Smooth Muscle Tumor and Its Genomic Analysis

  Miyahara J, Shimazu K, Saito A, Saito M, Fukuda K, Yoshida T, Taguchi D, Shinozaki H, Takahashi N, Nanjo H, Shibata H. Case Rep Oncol. 2023 Aug 4;16(1):577-584.

• Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406

  Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K , Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Kameoka Y, Takayama N, Hanamura I, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K, Nagai H. Cancer Sci. 2023 Aug;114(8):3461-3465.

• c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma

  Osada N, Kikuchi J, Iha H, Yasui H, Ikeda S, Takahashi N, Furukawa Y. Clin Transl Med. 2023 Aug;13(8):e1364.

• Acute Myeloid Leukemia Harboring the t(16;21) (p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation

  Teshima K, Ikeda S, Abe K, Yamada M, Takahashi N. Case Reports Cureus. 2023 Jul 20;15(7):e42215.

• The hepatic niche leads to aggressive natural killer cell leukemia proliferation through the transferrin-transferrin receptor 1 axis

  Kameda K, Yanagiya R, Miyatake Y, Carreras J, Higuchi H, Murayama H, Ishida T, Ito A, Iida S, Fukuhara N, Harigae H, Fujioka Y, Takahashi N, Wada H, Ishida F, Nakazawa H, Ishihara R, Murakami Y, Tagawa H, Matsuura T, Nakagawa S, Iwabuchi S, Hashimoto S, Imadome KI, Nakamura N, Ishizawa K, Kanda Y, Ando K, Kotani A. Blood. 2023 Jul 27;142(4):352-364.

• Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL

  Onishi Y, Furukawa E, Kamata M, Fukatsu M, Kameoka Y, Hatta S, Hamada H, Oyake T, Kai T, Sukegawa M, Nakajima S, Yanagiya R, Yamaguchi K, Takahashi T, Harazaki Y, Izumi T, Murai K, Ito S, Ikezoe T, Ishizawa K, Takahashi N, Harigae H. nt J Hematol. 2023 May;117(5):738-747.

• Comparative proteomic analysis of glomerular proteins in IgA nephropathy and IgA vasculitis with nephritis

  Kaga H, Matsumura H, Saito A, Saito M, Abe F, Suzuki T, Dohmae N, Odaka M, Komatsuda A, Wakui H, Takahashi N. Clin Proteomics. 2023 May 13;20(1):21.

• Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome-positive acute lymphoblastic leukaemia patients

  Fukushi Y, Akamine Y, Abumiya M, Tozawa N, Yamashita T, Nara M, Kameoka Y, Takahashi N, Miura M. Br J Clin Pharmacol. 2023 May;89(5):1695-1700.

• Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01

  Hosono N, Chi S, Yamauchi T, Fukushima K, Shibayama H, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Usuki K, Utsu Y, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Kojima K, Nakamura Y, Fukuhara S, Izutsu K, Abutani H, Yamauchi N, Yuda J, Minami Y; All HM-SCREEN-Japan 01 Investigators. Cancer Sci. 2023 May;114(5):2098-2108.

• Improving performance and self-efficacy of novice nurses using hybrid simulation-based mastery learning

  Takashiki R, Komatsu J, Nowicki M, Moritoki Y, Okazaki M, Ohshima S, Hasegawa H, Nomura K, Ouchi G, Berg BW, Shirakawa H, Nakayama K, Takahashi N. Jpn J Nurs Sci. 2023 Apr;20(2):e12519.

• Hypoxia-induced oxidative stress promotes therapy resistance via upregulation of heme oxygenase-1 in multiple myeloma

  Abe K, Ikeda S, Nara M, Kitadate A, Tagawa H, Takahashi N. Cancer Med. 2023 Apr;12(8):9709-9722.

• Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML

  Ono T, Takahashi N, Kizaki M, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Naoe T, Matsumura I. Cancer Sci. 2023 Mar;114(3):995-1006.

• Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study

  Yuda J, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, Matsumura I, Kubo K, Goto T, Kirito K, Maki A, Aoki M , Allepuz A, Minami Y. Cancer Med.2023 Feb;12(3):2990-2998.

• Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor

  Takahashi N, Kameoka Y, Onizuka M, Onishi Y, Takahashi F, Dan T, Miyata T, Ando K, Harigae H. Cancer Med.2023 Feb;12(4):4250-4258.

• EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress

  Kikuchi J, Kodama N, Takeshita M, Ikeda S, Kobayashi T, Kuroda Y, Uchiyama M, Osada N, Bogen B, Yasui H, Takahashi N, Miwa A, Furukawa Y. Blood Adv. 2023 Feb 28;7(4):508-524.

• Ovarian Follicular Lymphoma Diagnosed due to Hydronephrosis

  Noguchi S, Kimura Y, Shibano S, Ariake C, Iwasawa T, Oyama N, Sato H, Enomoto K and Takahashi N. Intern Med. 2023 Jan 15;62(2):293-298.

2022年

• Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients

  Imamura K, Izumi Y, Banno H, Uozumi R, Morita S, Egawa N, Ayaki T, Nagai M, Nishiyama K, Watanabe Y, Hanajima R, Oki R, Fujita K, Takahashi N, Ikeda T, Shimizu A, Morinaga A, Hirohashi T, Fujii Y, Takahashi R, Inoue H. BMJ Open. 2019 Dec 2;9(12):e033131.　　　

• Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia

  Sato H, Kobayashi T, Fujita N, Yamashita T, Kitadate A, Yoshioka T, Nara M, Kameoka Y, Miura M, Takahashi N. Cancer Chemother Pharmacol. 2022 Sep;90(3):279-284.

• Comparative proteomic analysis of glomerular proteins in primary and bucillamine‑induced membranous nephropathy

  Kaga H, Matsumura H, Suzuki T, Dohmae N, Odaka M, Komatsuda A, Takahashi N, Wakui H. Clin Proteomics. 2022 Jul 14;19(1):26.

• Refractory IgG4-related disease complicated with organising pneumonia and hypertrophic pachymeningitis

  Abe F, Michishita Y, Saito M, Nara M, Wakui H, Takahashi N. Mod Rheumatol Case Rep . 2022 Jun 23;6(2):278-281.

• Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy

  Fukuda N, Akamine Y, Abumiya M, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N, Miura M.Cancer Chemother Pharmacol. 2022 May;89(5):609-616.

• [Postmortem diagnosis of intravascular large B-cell lymphoma after atraumatic splenic rupture due to splenic infiltration]

  Kuroki W, Kobayashi T, Umakoshi M, Kitadate A, Imaizumi C, Saito M, Kobayashi I, Fujishima M, Fujishima N, Yoshioka T, Goto A,Takahashi N. Rinsho Ketsueki. 2022;63(6):523-529.

• High baseline total lesion glycolysis predicts early progression of disease within 24 months in patients with high-tumor-burden follicular lymphoma

  Kuroki W, Kitadate A, Ishiyama K, Kameoka Y, Takahashi N. Int J Hematol . 2022 Nov;116(5):712-722.

• Long-term prognosis of monoclonal immunoglobulin-associated glomerular diseases with non-organized deposits: A report of 38 cases from a Japanese single center

  Nara M, Komatsuda A, Sawamura M, Abe F, Kaga H , Saito A, Saito M, Imaizumi C, Nanjo H, Wakui H, Takahashi N. Clin Nephrol . 2022 Sep;98(3):135-145.

• Evaluation of a newly proposed renal risk score for Japanese patients with ANCA-associated glomerulonephritis

  Saito M, Saito A, Abe F, Imaizumi C, Kaga H, Sawamura M, Nara M, Ozawa M, Sato R, Nakayama T, Okuyama S, Masai R, Ohtani H, Komatsuda A, Wakui H, Takahashi N. Clin Exp Nephrol. 2022 Aug;26(8):760-769.

• Refractory IgG4-Related Disease Complicated With Organizing Pneumonia and Hypertrophic Pachymeningitis

  Abe F, Michishita Y, Saito M, Nara M, Wakui H, Takahashi N. Mod Rheumatol Case Rep. 2022 Jun 23;6(2):278-281.

• Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma

  Murayama K, Kiguchi T, Izutsu K, Kameoka Y, Hidaka M, Kato H, Rai S, Kuroda J, Ishizawa K, Ichikawa S, Ando K, Ogura M, Fukushima K, Terui Y. Ann Hematol. 2022 May;101(5):979-989.

• Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy

  Fukuda N, Akamine Y, Abumiya M, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N, Miura M. Cancer Chemother Pharmacol. 2022 May;89(5):609-616.

• Adult-onset Still’s Disease During Pregnancy Treated with Tocilizumab

  Imaizumi C, Saito M, Abe F, Kaga H, Saito A, Nara M, Kameyama S, Miura H, Ogasawara H, Hirakawa T, Mizunuma M, Satoh M, Komatsuda A, Terada Y, Takahashi N. Intern Med. 2022 Oct 15;61(20):3137-3140.

• Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis

  Naoto Takahashi, Jorge E. Cortes, Emiko Sakaida, Kenichi Ishizawa, Takaaki Ono, Noriko Doki, Itaru Matsumura, Valentín García‑Gutiérrez, Gianantonio Rosti, Chiho Ono, Masayuki Ohkura, Yusuke Tanetsugu, Andrea Viqueira, Tim H. Brümmendorf. Int J Hematol . 2022 Jun;115(6):838-851.

• Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma

  Miyazaki K, Suzuki R, Oguchi M, Taguchi S, Amaki J, Maeda T, Kubota N, Maruyama D, Terui Y, Sekiguchi N, Takizawa J, Tsukamoto H, Murayama T, Ando T, Matsuoka H, Hasegawa M, Wada H, Sakai R, Kameoka Y, Tsukamoto N, Choi I, Masaki Y, Shimada K, Fukuhara N, Utsumi T, Uoshima N, Kagami Y, Asano N, Ejima Y, Katayama N, Yamaguchi M. Hematol Oncol. 2022 Oct;40(4):667-677.

• Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma

  Matsuda Y, Ikeda S, Abe F, Takahashi Y, Kitadate A, Takahashi N, Wakui H, Tagawa H. Cancer Sci . 2022 Apr;113(4):1208-1219.

• Advanced Tertiary Lymphoid Tissues in Protocol Biopsies are Associated with Progressive Graft Dysfunction in Kidney Transplant Recipients

  Lee Y-H, Sato Y, Saito M, Fukuma S, Saito M, Yamamoto S, Komatsuda A, Fujiyama N, Satoh S, Lee S-H, Boor P, Habuchi T, Floege J, Yanagita M. J Am Soc Nephrol. 2022 Jan;33(1):186-200.

• Successful rituximab treatment of an elderly Japanese patient with HHV8-positive, HIV-negative multicentric Castleman disease

  Kaga H, Kurahashi H, Kubota A, Hatano Y, Nanjo H, Wakui H, Takahashi N. Int J Hematol. 2022 Jan;115(1):129-134.

2021年

• Comment on skin biopsies for diagnosing intravascular lymphoma: A retrospective study of diagnostic accuracy

  Enzan N, Kitadate A, Kono M. J Am Acad Dermatol. 2023 Jan;88(1):e47-e48.

• Successful salvage therapy of D-PACE combined with pomalidomide in a patient with triple-class refractory secondary plasma cell leukemia.

  Kobayashi T, Kuroki J, Kobayashi I, Saito M, Fujishima M, Ubukawa K, Fujishima N, Kameoka Y, Nanjo H and Takahashi N. Int J Myeloma. 2021; 11(4), 27–31.

• Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1)

  Nakamura N, Maruyama D, Machida R, Ichinohe T, Takayama N, Ohba R, Ohmachi K, Imaizumi Y, Tokunaga M, Katsuya H, Yoshida I, Sunami K, Kurosawa M, Kubota N, Morimoto H, Kobayashi M, Kato H, Kameoka Y, Kagami Y, Kizaki M, Takeuchi K, Munakata W, Iida S, Nagai H. Jpn J Clin Oncol. 2021 Jul 1;51(7):1059-1066.

• Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis:A Randomized Clinical Trial

  Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, Umibe T, Kono H, Kurasawa K, Kita Y, Matsumura R, Kaneko Y, Ninagawa K, Hiromura K, Kagami S, Inaba Y, Hanaoka H, Ikeda K, Nakajima H for the LoVAS Collaborators. JAMA. 2021 Jun 1;325(21):2178-2187.

• Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update

  Timothy P. Hughes, Nelma Cristina D. Clementino, Mikhail Fominykh, Jeffrey H. Lipton, Anna G. Turkina, Elena Beatriz Moiraghi, Franck E. Nicolini, Naoto Takahashi, Tomasz Sacha, Dong-Wook Kim, Rafik Fellague-Chebra, Ranjan Tiwari, Catherine Bouard, Francois-Xavier Mahon. Leukemia. 2021 Jun;35(6):1631-1642.

• Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia

  Fujioka Y, Sugiyama D, Matsumura I, Minami Y, Miura M, Atsuta Y, Ohtake S, Kiyoi H, Miyazaki Y, Nishikawa H and Takahashi N. cancers. 2021; 13(23), 5904

• Methotrexate-induced Transient Encephalopathy in an Adolescent and Young Adult Patient with Acute Lymphoblastic Leukemia

  Teshima K, Kume M, Kondo R, Shibata K, Abe K, Aono H, Fushimi S, Takahashi S, Takahashi S, Saito M, Takahashi N. Intern Med. 2021 Jul 1;60(13):2115-2118.

• Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia

  Ochi Y, Yoshida K, Huang Y-J , Kuo M-C, Nannya Y, Sasaki K, Mitani K, Hosoya N, Hiramoto N, Ishikawa T, Branford S, Shanmuganathan N, Ohyashiki K, Takahashi N, Takaku T Tsuchiya S, Kanemura N, Nakamura N, Ueda Y, Yoshihara S, Bera R, Shiozawa Y, Zhao L, Takeda J, Watatani Y, Okuda R, Makishima H, Shiraishi Y, Chiba K, Tanaka H, Sanada M, Takaori-Kondo A, Miyano S, Ogawa S, Shih L-Y. Nat Commun . 2021 May 14;12(1):2833.

• Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL

  Kawano N, Kimura S, Miura M, Tochigi T, Nakaike T, Yamashita K, Mashiba K, Kikuchi I, Takahashi N. Int J Hematol. 2021 Oct;114(4):509-516.

• Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma

  Ikeda S, Tagawa H. Cancer Sci. 2021 Oct;112(10):3995-4004.

• IL-6 Generated from Human Hematopoietic Stem and Progenitor Cells through TLR4 Signaling Promotes Emergency Granulopoiesis by Regulating Transcription Factor Expression

  Sasaki Y, Guo Y-M, Goto T, Ubukawa K, Asanuma K, Kobayashi I, Sawada K, Wakui H, Takahashi N. J Immunol. 2021 Aug 15;207(4):1078-1086.

• Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence

  Kitadate A, Terao T, Narita K, Ikeda S, Takahashi Y, Tsushima T, Miura D, Takeuchi M, Takahashi N, Matsue K. Cancer Sci. 2021 Sep;112(9):3645-3654.

• VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience

  Ozawa M, Ohtani H, Komatsuda A, Wakui H, Takahashi N. Clin Exp Nephrol. 2021 Nov;25(11):1193-1202.

• Flow cytometry analysis of peripheral Tregs in patients with multiple myeloma under lenalidomide maintenance

  Nozaki K, Fujioka Y, Sugiyama D, Ishikawa J, Iida M, Shibata M, Kosugi S, Nishikawa H, Shibayama H. Int J Hematol. 2021 May;113(5):772-774.

• Effects of proprotein convertase subtilisin/kexin type 9 and nilotinib plasma concentrations on nilotinib-induced hypercholesterolaemia in patients with chronic myeloid leukaemia.

  Abumiya M, Akamine Y, Sato S, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N, Miura M.J Clin Pharm Ther. 2021 Apr;46(2):382-387.

• Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy

  Abumiya M, Takahashi N, Takahashi S, Yoshioka T, Kameoka Y & Miura M. Sci Rep. 2021 Mar 8;11(1):6362.

• Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis

  Kobayashi T, Ubukawa K, Fujishima M, Takahashi N.Int J Hematol. 2021 Apr;113(4):600-605.

• Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance

  Abumiya M, Takahashi N, Yoshioka T, Kameoka Y, Miura M. J Clin Pharm Ther. 2021 Feb;46(1):219-222.

• The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration

  Ito F, Miura M, Fujioka Y, Abumiya M, Kobayashi T, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N. Int J Hematol. 2021 Jan;113(1):100-105.

• Finger joint cartilage evaluated by semi-quantitative ultrasound score in patients with rheumatoid arthritis.

  Ogura T, Hirata A, Hayashi N, Imaizumi C, Ito H, Takenaka S, Inoue Y, Takakura Y, Mizushina K, Katagiri T, Kameda H. Arthritis Care Res (Hoboken). 2021 Feb;73(2):173-179.

2020年

• Pre-treatment metabolic tumour volume and total lesion glycolysis are superior to conventional positron-emission tomography/computed tomography variables for outcome prediction in patients with newly diagnosed multiple myeloma in clinical practice

  Terao T, Machida Y, Tsushima T, Miura D, Narita K, Kitadate A, Takeuchi M, Matsue M. Clinical Trial Br J Haematol. 2020 Oct;191(2):223-230.

• The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia.

  Taniguchi Y, Takahashi N, Miura M, Hirase C, Sueda S, Espinoza JL, Rai S, Nakayama S, Serizawa K, Kumode T, Watatani Y, Morita Y, Tanaka H, Matsumura I.Intern Med. 2020 Nov 1;59(21):2745-2749.

• Hypereosinophilic syndrome with abundant Charcot-Leyden crystals in spleen and lymph nodes.

  Takeda M, Ueki S, Yamamoto Y, Nara M, Fukuchi M, Nakayama K, Omori Y, Takahashi N, Hirokawa M.Asia Pac Allergy. 2020 Jul 8;10(3):e24.

• Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia.

  Hino M, Matsumura I, Fujisawa S, Ishizawa K, Ono T, Sakaida E, Sekiguchi N, Tanetsugu Y, Fukuhara K, Ohkura M, Koide Y, Takahashi N.Int J Hematol. 2020 Jul;112(1):24-32.

• Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma

  Kitadate A, Narita K, Fukumoto K, Terao T, Tsushima T, Kobayashi H, Abe Y, Miura D, Takeuchi M, Machida Y, Matsue K. Cancer Med. 2020 Aug;9(15):5509-5518.

• Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor

  Ono T, Takahashi N, Kizaki M, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Naoe T, Matsumura I. Cancer Science. 2020 Oct;111:3714–3725.

• Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma

  Ikeda S, Abe F, Matsuda Y, Kitadate A, Takahashi N, Tagawa H. Cancer Sci. 2020 Nov;2020;111:4088–4101.

• Multiple Myeloma–Associated Ig Light Chain Crystalline Cast Nephropathy

  Matsumura H, Furukawa Y, Nakagaki T, Furutani C, Osanai S, Noguchi K, Odaka M, Yohda M, Ohtani H, Michishita Y, Kawabata Y, Kitabayashi A, Ikeda S, Nara M, Komatsuda A, Takahashi N and Wakui H. Kidney Int Rep. 2020 Sep; 5(9): 1595–1602.

• Outcome of colorectal cancer in Diamond–Blackfan syndrome with a ribosomal protein S19 mutation

  Kimura K, Shimazu K, Toki T, Misawa M, Fukuda K, Yoshida T, Taguchi D, Fukuda S, Iijima K, Takahashi N, Ito E, Nanjyo H, Shibata H. Clin J Gastroenterol. 2020 Dec;13(6):1173-1177.

• CD7-Positive Diffuse Large B-Cell Lymphoma Presenting as an Intranasal Tumor

  Teshima K, Kume M, Kawaharada Y, Saito T, Abe K, Ikeda S, Ohyagi H, Zuguchi M, Zuguchi M, Kubota Y, Enomoto Y, Miura M, Takahashi S, Saito M, Saito K, Takahashi N. Case Rep Hematol. 2020 Apr 12;2020:1514729.

• Comparative proteomic analysis of renal proteins from IgA nephropathy model mice and control mice

  Miyakawa R, Sato A, Matsuda Y, Saito A, Abe F, Matsumura H, Odaka M, Suzuki T, Dohmae N, Komatsuda A. Takahashi N, Wakui H. Clin Exp Nephrol. 2020 Aug;24(8):666-679.

• Cdc42 regulates cell polarization and contractile actomyosin rings during terminal differentiation of human erythroblasts

  Ubukawa K, Goto T, Asanuma K, Sasaki Y, Yong-Mei Guo, Kobayashi I, Sawada K, Wakui H, Takahashi N. Sci Rep. 2020 Jul 16;10(1):11806.

• Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line.

  Sakurai M, Okamoto S, Matsumura I, Murakami S, Takizawa M, Waki M, Hirano D, Watanabe-Nakaseko R, Kobayashi N, Iino M, Mitsui H, Ishikawa Y, Takahashi N, Kawaguchi T, Suzuki R, Yamamoto K, Kizaki M, Ohnishi K, Naoe T, Akashi K; New TARGET investigators. Int J Hematol. 2020 Jun;111(6):812-825.

• An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.

  Ko TK, Javed A, Lee KL, Pathiraja TN, Liu X, Malik S, Soh SX, Heng XT, Takahashi N, Tan JHJ, Bhatia R, Khng AJ, Chng WJ, Sia YY, Fruman DA, Ng KP, Chan ZE, Xie KJ, Hoi Q, Chan CX, Teo ASM, Velazquez O, Meah WY, Khor CC, Ong CT, Soon WW, Tan P, Ng PC, Chuah C, Hillmer AM, Ong ST. Blood. 2020 Jun 25;135(26):2337-2353.

• Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease.

  Mori J, Oshima K, Tanimoto T, Ishizuka H, Kimura S, Miura M, Takahashi N. Int J Hematol. 2020 Jul;112(1):115-117.

• Clinicopathological features and outcomes of diabetic kidney disease with extracapillary hypercellularity:a Japanese single-center experience.

  Saito A, Komatsuda A, Saito M, Koga H, Abe F, Sawamura M, Nara M, Sato R, Wakui H, Takahashi N. Clin Exp Nephrol. 2020 Jun; 24(6): 509-517.

• Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells.

  Tanaka A, Nishikawa H, Noguchi S, Sugiyama D, Morikawa H, Takeuchi Y, Ha D, Shigeta N, Kitawaki T, Maeda Y, Saito T, Shinohara Y, Kameoka Y, Iwaisako K, Monma F, Ohishi K, Karbach J, Jäger E, Sawada K, Katayama N, Takahashi N, Sakaguchi S. J Exp Med. 2020 Feb; 217(2): e20191009.

• Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients.

  Kitadate A, Kobayashi H, Abe Y, Narita K, Miura D, Takeuchi M, Matsue K. Haematologica. 2020 Jan; 105(1): e37-e40.

2019年

1. A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.

   Fuchida SI, Sunami K, Matsumoto M, Okumura H, Murayama T, Miyamoto T, Otsuka E, Fujishima N, Izumi T, Tamaki S, Hiramatsu Y, Kuroda Y, Shimazaki C, Akashi K, Harada M, on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT). Int J Hemato. 2019 Jan; 109(1):107-114.

2. Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients

   Sasaki T, Franco OE, Ohishi K, Filipovich Y, Ishii K, Crawford SE, Takahashi N, Katayama N, Sugimura Y, Hayward SW. Prostate. 2019 Feb; 79(3): 259-264.

3. Relationship between clinical course of nivolumab-related myositis and immune status in a patient with Hodgkin’s lymphoma after allogeneic hematopoietic stem cell transplantation.

   Kobayashi T, Guo Y-M, Yamashita T, Nara M, Yoshioka T, Kameoka Y, Fukuda T, Takahashi N. Int J Hematol. 2019 Mar; 109(3): 356-360.

4. Myeloablative and reduced-intensity conditioning in HLA haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide.

   Sugita J, Kagaya Y, Miyamoto T, Shibasaki Y, Nagafuji K, Ota S, Furukawa T, Nara M, Akashi K, Taniguchi S, Harada M, Matsuo K, Teshima T, on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT). Bone Marrow Transplantation. 2019 Mar; 54(3): 432-441.

5. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.

   Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T, the New TARGET investigators. Int J Hematol. 2019 Apr; 109(4):426-439.

6. Pharmacokinetics of Tacrolimus Coadministered With Letermovir in Allogeneic Hematopoietic Stem Cell Transplantation Patients.

   Guo Y-M, Abumiya M, Yamashita T, Ubukawa K and Takahashi N. Clin Pharmacol Drug Dev. 2019 Apr; 8(3): 411-412.

7. ATP produced by anaerobic glycolysis is essential for enucleation of human erythroblasts.

   Goto T, Ubukawa K, Kobayashi I, Sugawara K, Asanuma K, Sasaki Y, Guo Y-M, Takahashi N, Sawada K, Wakui H, Nunomura W. Exp Hematol. 2019 Apr; 72: 14-26.

8. Comparison of measurements of anti-PLA2R antibodies in Japanese patients with membranous nephropathy using in-house and commercial ELISA.

   Kaga H, Komatsuda A, Yamamoto S, Kikuchi T, Kamata M, Sato A, Odaka M, Yokota SI, Takahashi N, Wakui H. Clin Exp Nephrol. 2019 Apr; 23(4): 465-473.

9. Dasatinib and low-intensity chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia in a child with Down syndrome.

   Hirabayashi S, Hasegawa D, Yamamoto K, Nishimura A, Hosoya Y, Shuo T, Kiyokawa N, Miura M, Takahashi N, Manabe A. Pediatr Blood Cancer. 2019 May; 66(5): e27612.

10. Influence of ABCB1 polymorphisms on the pharmacokinetics and toxicity of lenalidomide in patients with multiple myeloma.

    Kobayashi T, Miura M, Abumiya M, Akamine Y, Ito F, Takahashi N. Med Oncol. 2019 May; 36(6): 55.

11. Diagnostic and Prognostic Value of Using 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Peripheral T-Cell Lymphoma.

    Abe Y, Kitadate A, Usui Y, Narita K, Kobayashi H, Miura D, Takeuchi M, O'uchi E, O'uchi T, Matsue K. Clin Nucl Med. 2019 May; 44(5): e336-e341.

12. Low hexokinase-2 expression-associated false-negative 18F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma.

    Abe Y, Ikeda S, Kitadate A, Narita K, Kobayashi H, Miura D, Takeuchi M, Ouchi E, Ouchi T, Matsue K. Eur J Nucl Med Mol Imaging. 2019 Jun; 46(6): 1345-1350.

13. High-throughput sequencing of IgG B-cell receptors reveals frequent usage of the rearranged IGHV4-28/ IGHJ4 gene in primary immune thrombocytopenia.

    Hirokawa M, Fujishima N, Togashi M, Saga A, Omokawa A, Saga T, Moritoki Y, Ueki S, Takahashi N, Kitaura K, Suzuki R. Sci Rep. 2019 Jun; 9(1): 8645.

14. Effect of low platelet HLA-C expression on donor-specific antibody depletion following platelet transfusion from a corresponding HLA donor.

    Yamashita T, Ikegame K, Ito F, Kobayashi T, Nara M, Fujishima N, Anbai A, Inoue T, Kaida K, Tanaka H, Takahash N. Bone Marrow Transplant. 2019 Oct; 54(10): 1713-1716.

15. Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency.

    Guo Y-M, Takahashi N, Miyabe K, Yoshida M, Abe F, Yamashita T, Nara M, Yoshioka T, Ohashi K, Goto A, Takahashi N. Intern Med.2019 Oct; 58(20): 3039-3043.

16. Membranous nephropathy with solitary polyclonal IgA deposition: A case report and literature review.

    Sawamura M, Komatsuda A, Kaga H, Saito A, Yasuda T, Wakui H, Joh K, Takahashi N. Clin Nephrol Case Stud. 2019 Oct; 7: 60-65.

17. Thrombocytopenia Caused by a Tea Beverage of Taxus yunnanensis (Chinese Yew).

    Ubukawa K, Kameoka Y, Guo Y-M, Nara M, Watanabe A, Fujishima M, Fujishima N, Yoshioka T and Takahashi N. Intern Med. 2019 Nov; 58(21): 3153-3156.

18. Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone.

    Ikeda S, Kobayashi T, Saito M, Komatsuda A, Ubukawa K, Kameoka Y, Takahashi N. Intern Med. 2019 Dec; 58(23): 3461-3468.

19. A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.

    Nara M, Saito M, Abe F, Komatsuda A, Wakui H, Takahashi N. Intern Med. 2019 Dec; 58(24): 3583-3587.

20. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.

    Imamura K, Izumi Y, Banno H, Uozumi R, Morita S, Egawa N, Ayaki T, Nagai M, Nishiyama K, Watanabe Y, Hanajima R, Oki R, Fujita K, Takahashi N, Ikeda T, Shimizu A, Morinaga A, Hirohashi T, Fujii Y, Takahashi R, Inoue H. BMJ Open. 2019 Dec; 9(12): e033131.

2018年

1. Phase II clinical trial of lenalidomide and dexamethasone therapy in Japanese elderly patients with newly diagnosed multiple myeloma to determine optimal plasma concentration of lenalidomide.

   Kobayashi T, Miura M, Niioka T, Abumiya M, Ito F, Kobayashi I, Ikeda S, Yoshioka T, Kameoka Y, Takahashi N. Ther Drug Monit. 2018 Feb 27. doi: 10.1097/FTD.0000000000000499. [Epub ahead of print]

2. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.

   Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP. Ann Intern Med. 2018 Apr 3;168(7):461-470. doi: 10.7326/M17-1094. Epub 2018 Feb 20.

3. Hypoxia-inducible KDM3A addiction in multiple myeloma.

   Ikeda S, Kitadate A, Abe F, Takahashi N, Tagawa H. Blood Adv. 2018 Feb 27;2(4):323-334. doi: 10.1182/bloodadvances.2017008847.

4. The potential role of clarithromycin addition to lenalidomide and dexamethasone therapy (BiRd) in multiple myeloma.

   Kobayashi T, Miura M, Abumiya M, Niioka T, Kanno S, Takahashi N. Ann Hematol. 2018 Feb 9. doi: 10.1007/s00277-018-3270-4. [Epub ahead of print] No abstract available.

5. Different clonal dynamics of chronic myeloid leukaemia between bone marrow and the central nervous system.

   Ogawa M, Yokoyama K, Hirano M, Jimbo K, Ochi K, Kawamata T, Ohno N, Shimizu E, Yokoyama N, Yamaguchi R, Imoto S, Uchimaru K, Takahashi N, Miyano S, Imai Y, Tojo A. Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15065. [Epub ahead of print] No abstract available.

6. [Refractory CD20-positive peripheral T-cell lymphoma showing loss of CD20 expression after rituximab therapy and gain of CD20 expression after administration of vorinostat and gemcitabine].

   Teshima K, Ohyagi H, Kume M, Takahashi S, Saito M, Takahashi N. Rinsho Ketsueki. 2017;58(11):2227-2231. doi: 10.11406/rinketsu.58.2227. Japanese.

7. Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients.

   Abumiya M, Miura M, Takahashi N. Leuk Res. 2018 Jan;64:42-45. doi: 10.1016/j.leukres.2017.11.012. Epub 2017 Nov 22.

8. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.

   Kitadate A, Ikeda S, Abe F, Takahashi N, Shimizu N, Matsue K, Tagawa H. Haematologica. 2018 Jan;103(1):126-135. doi: 10.3324/haematol.2017.177279. Epub 2017 Oct 12.

9. Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis Complicated by Periaortitis and Cranial Hypertrophic Pachymeningitis: A Report of an Autopsy Case.

   Kaga H, Komatsuda A, Saito M, Nara M, Omokawa A, Togashi M, Okuyama S, Wakui H, Takahashi N. Intern Med. 2018 Jan 1;57(1):107-113. doi: 10.2169/internalmedicine.8751-16. Epub 2017 Oct 11.

10. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

    Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, Miyata Y, Kobayashi S, Usuki K, Matsumura I, Minami Y, Usui N, Fukuda T, Takada S, Ishikawa M, Fujimaki K, Gomyo H, Sasaki O, Ohishi K, Miyake T, Imai K, Suzushima H, Mitsui H, Togitani K, Kiguchi T, Atsuta Y, Ohtake S, Ohnishi K, Kobayashi Y, Kiyoi H, Miyazaki Y, Naoe T; Japan Adult Leukemia Study Group. Int J Hematol. 2018 Feb;107(2):185-193. doi: 10.1007/s12185-017-2334-x. Epub 2017 Sep 19.

11. Clinicopathological and long-term prognostic features of membranous nephropathy with crescents: a Japanese single-center experience.

    Saito M, Komatsuda A, Sato R, Saito A, Kaga H, Abe F, Sawamura M, Nara M, Togashi M, Okuyama S, Wakui H, Takahashi N. Clin Exp Nephrol. 2018 Apr;22(2):365-376. doi: 10.1007/s10157-017-1465-y. Epub 2017 Aug 29.

12. Analysis of PLA2R1 and HLA-DQA1 sequence variants in Japanese patients with idiopathic and secondary membranous nephropathy.

    Kaga H, Komatsuda A, Omokawa A, Okuyama S, Mori K, Wakui H, Takahashi N. Clin Exp Nephrol. 2018 Apr;22(2):275-282. doi: 10.1007/s10157-017-1471-0. Epub 2017 Aug 28.

13. Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia.

    Mita A, Abumiya M, Miura M, Niioka T, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N. Exp Hematol Oncol. 2018 Apr 13;7:9. doi: 10.1186/s40164-018-0101-1. eCollection 2018.

14. Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.

    Noguchi S, Nakaseko C, Nishiwaki K, Ogasawara H, Ohishi K, Tokuhira M, Noguchi M, Kimura H, Handa H, Mitani K, Miura M, Wakita H, Takahashi N; STAT study group. Int J Hematol. 2018 Aug;108(2):176-183. doi: 10.1007/s12185-018-2459-6. Epub 2018 Apr 30.

15. Effects of polymorphisms in NR1I2, CYP3A4, and ABC transporters on the steady-state plasma trough concentrations of bosutinib in Japanese patient with chronic myeloid leukemia.

    Abumiya M, Mita A, Takahashi S, Yoshioka T, Kameoka Y, Takahashi N, Miura M. Med Oncol. 2018 May 7;35(6):90. doi: 10.1007/s12032-018-1146-z.

16. Influence of CYP3A5 genetic differences in tacrolimus on quantitative interstitial fibrosis and long-term graft function in kidney transplant recipients.

    Komine N, Satoh S, Saito M, Numakura K, Inoue T, Tsuruta H, Narita S, Komatsuda A, Nanjo H, Kagaya H, Niioka T, Miura M, Mitobe Y, Habuchi T. Int Immunopharmacol. 2018 May;58:57-63. doi: 10.1016/j.intimp.2018.03.004. Epub 2018 Mar 15.

17. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.

    Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, Nosaka K, Tsukamoto N, Shimoyama T, Fukuhara N, Yakushijin Y, Ohnishi K, Miyazaki K, Sawada K, Takayama N, Hanamura I, Nagai H, Kobayashi H, Usuki K, Kobayashi N, Ohyashiki K, Utsumi T, Kumagai K, Maruyama D, Ohmachi K, Matsuno Y, Nakamura S, Hotta T, Tsukasaki K; Japan Clinical Oncology Group- Lymphoma Study Group (JCOG-LSG). Cancer Sci. 2018 Sep;109(9):2830-2840. doi: 10.1111/cas.13719. Epub 2018 Jul 28.

18. Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma.

    Kameoka Y, Akagi T, Murai K, Noji H, Kato Y, Sasaki O, Ito S, Ishizawa K, Ishida Y, Ichinohasama R, Harigae H, Takahashi N. Int J Hematol. 2018 Nov;108(5):510-515. doi: 10.1007/s12185-018-2508-1. Epub 2018 Jul 24.

19. The localization of α-synuclein in the process of differentiation of human erythroid cells.

    Araki K, Sugawara K, Hayakawa EH, Ubukawa K, Kobayashi I, Wakui H, Takahashi N, Sawada K, Mochizuki H, Nunomura W. Int J Hematol. 2018 Aug;108(2):130-138. doi: 10.1007/s12185-018-2457-8. Epub 2018 Apr 24.

20. Disappearance of a thrombotic microangiopathy-like glomerular lesion in a patient with a placental site trophoblastic tumor after hysterectomy.

    Sawamura M, Komatsuda A, Nara M, Togashi M, Wakui H, Takahashi N. Clin Nephrol Case Stud. 2018 Sep 20;6:27-30. doi: 10.5414/CNCS109440. eCollection 2018.

21. Identification of a two-SNP PLA2R1 Haplotype and HLA-DRB1 Alleles as Primary Risk Associations in Idiopathic Membranous Nephropathy.

    Latt KZ, Honda K, Thiri M, Hitomi Y, Omae Y, Sawai H, Kawai Y, Teraguchi S, Ueno K, Nagasaki M, Mabuchi A, Kaga H, Komatsuda A, Tokunaga K, Noiri E. Sci Rep. 2018 Oct 22;8(1):15576. doi: 10.1038/s41598-018-33612-7.

22. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan.

    Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, Kuroki J, Kimura H, Tokuhira M, Mitani K, Fujikawa K, Iwase O, Ohishi K, Kimura F, Fukuda T, Tanosaki S, Takahashi S, Kameoka Y, Nishikawa H, Wakita H; STAT study group. Haematologica. 2018 Nov;103(11):1835-1842. doi: 10.3324/haematol.2018.194894. Epub 2018 Jul 5.

23. Released washed platelet concentrates are effective and safe in patients with a history of transfusion reactions.

    Fujiwara SI, Fujishima N, Kanamori H, Ito M, Sugimoto T, Saito S, Sakaguchi T, Nagai K, Masuoka H, Nagai K, Morita A, Kino S, Tanaka A, Hasegawa Y, Yokohama A, Fujino K, Makino S, Matsumoto M, Takeshita A, Muroi K. Transfus Apher Sci. 2018 Dec;57(6):746-751. doi: 10.1016/j.transci.2018.09.001. Epub 2018 Sep 7.

24. Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.

    Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K. Hematol Oncol. 2018 Dec;36(5):792-800. doi: 10.1002/hon.2559. Epub 2018 Sep 19.

2017年

1. Quantification of Interstitial Fibrosis in Renal Allografts and Clinical Correlates of Long-Term Graft Function.

   Nara M, Komatsuda A, Numakura K, Saito M, Inoue T, Niioka T, Miura M, Mitobe Y, Okuyama S, Takahashi N, Habuchi T, Satoh S. Am J Nephrol. 2017;46(3):187-194. doi: 10.1159/000479983. Epub 2017 Aug 22.

2. Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes.

   Niioka T, Fujishima N, Abumiya M, Yamashita T, Ubukawa K, Nara M, Fujishima M, Takahashi N, Miura M. Ther Drug Monit. 2017 Oct;39(5):514-521. doi: 10.1097/FTD.0000000000000441.

3. Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis.

   Fujishima M, Fujishima N, Kitadate A, Guo Y, Watanabe A, Ubukawa K, Nara M, Yoshioka T, Kameoka Y, Takahashi N. Rinsho Ketsueki. 2017;58(7):743-748. doi: 10.11406/rinketsu.58.743. Japanese.

4. Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation

   Doki N, Suyama M, Sasajima S, Ota J, Igarashi A, Mimura I, Morita H, Fujioka Y, Sugiyama D, Nishikawa H, Shimazu Y, Suda W, Takeshita K, Atarashi K, Hattori M, Sato E, Watakabe-Inamoto K, Yoshioka K, Najima Y, Kobayashi T, Kakihana K, Takahashi N, Sakamaki H, Honda K, Ohashi K. Ann Hematol. 2017 Sep;96(9):1517-1523. doi: 10.1007/s00277-017-3069-8. Epub 2017 Jul 21.

5. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.

   Tojo A, Kyo T, Yamamoto K, Nakamae H, Takahashi N, Kobayashi Y, Tauchi T, Okamoto S, Miyamura K, Hatake K, Iwasaki H, Matsumura I, Usui N, Naoe T, Tugnait M, Narasimhan NI, Lustgarten S, Farin H, Haluska F, Ohyashiki K. Int J Hematol. 2017 Sep;106(3):385-397. doi: 10.1007/s12185-017-2238-9. Epub 2017 Apr 25.

6. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.

   Takahashi N, Nakaseko C, Kobayashi Y, Miyamura K, Ono C, Koide Y, Fujii Y, Ohnishi K. Int J Hematol. 2017 Sep;106(3):398-410. doi: 10.1007/s12185-017-2239-8. Epub 2017 Apr 13.

7. Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids.

   Sawamura M, Komatsuda A, Togashi M, Wakui H, Takahashi N. Intern Med. 2017;56(6):631-636. doi: 10.2169/internalmedicine.56.7797. Epub 2017 Mar 17.

8. Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum.

   Yokoyama H, Takahashi N, Katsuoka Y, Inomata M, Ito T, Meguro K, Kameoka Y, Tsumanuma R, Murai K, Noji H, Ishizawa K, Ito S, Onishi Y, Harigae H; Tohoku Hematology Forum. Int J Hematol. 2017 May;105(5):606-613. doi: 10.1007/s12185-017-2190-8. Epub 2017 Feb 7.

9. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.

   Ikeda S, Kitadate A, Abe F, Saitoh H, Michishita Y, Hatano Y, Kawabata Y, Kitabayashi A, Teshima K, Kume M, Takahashi N, Tagawa H. Cancer Sci. 2017 Apr;108(4):641-652. doi: 10.1111/cas.13183. Epub 2017 Apr 20.

10. Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.

    Jiang ZP, Zhao XL, Takahashi N, Angelini S, Dubashi B, Sun L, Xu P. Pharmacogenomics. 2017 Jan;18(1):35-56. doi: 10.2217/pgs-2016-0103. Epub 2016 Dec 19.

11. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.

    Abe F, Kitadate A, Ikeda S, Yamashita J, Nakanishi H, Takahashi N, Asaka C, Teshima K, Miyagaki T, Sugaya M, Tagawa H. Oncotarget. 2017 Jan 31;8(5):7572-7585. doi: 10.18632/oncotarget.13810.

12. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.

    Komatsu N, Kirito K, Shimoda K, Ishikawa T, Ohishi K, Ohyashiki K, Takahashi N, Okada H, Amagasaki T, Yonezu T, Akashi K. Int J Hematol. 2017 Mar;105(3):309-317. doi: 10.1007/s12185-016-2130-z. Epub 2016 Nov 10. Erratum in: Int J Hematol. 2017 Mar;105(3):387.

13. Clinicopathological characteristics of malignant lymphoma in patients with hepatitis C virus infection in the Tohoku district in Eastern Japan.

    Tajima K, Takahashi N, Ishizawa K, Murai K, Akagi T, Noji H, Sasaki O, Wano M, Itoh J, Kato Y, Shichishima T, Harigae H, Ishida Y; Tohoku Hematology Forum. Leuk Lymphoma. 2017 Jun;58(6):1509-1511. doi: 10.1080/10428194.2016.1236376. Epub 2016 Oct 10.

14. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.

    Ozawa M, Komatsuda A, Ohtani H, Nara M, Sato R, Togashi M, Takahashi N, Wakui H. Clin Exp Nephrol. 2017 Apr;21(2):212-227. doi: 10.1007/s10157-016-1271-y. Epub 2016 Apr 26.